Actively Recruiting
Study of Single Ascending Doses of ABBV-1451 to Assess Safety, Pharmacokinetics, and Immune Response in Healthy Adults Including Japanese and Han Chinese Participants
Led by AbbVie · Updated on 2026-05-28
90
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying ABBV-1451 in healthy adult volunteers to understand how the drug moves through the body pharmacokinetics, the immune response it may trigger immunogenicity, and its safety and tolerability. This early phase 1 trial includes healthy participants, including specific groups of Japanese and Han Chinese adults, to gather important initial data about ABBV-1451. Participants will receive single ascending doses of ABBV-1451 through injections or infusions, with doses increasing stepwise until reaching one of several defined dose levels or a placebo. The study includes multiple groups, some receiving ABBV-1451 while others receive placebo, with special groups for Japanese and Han Chinese participants receiving a single dose at a certain level. During the study, participants will be closely monitored for side effects and drug levels in their blood up to about 211 days. Assessments include medical exams, vital signs, laboratory tests, ECGs, and tracking of any adverse events. This comprehensive monitoring helps researchers measure how the drug behaves and its safety profile over time in healthy adults.
CONDITIONS
Brief Title
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Ascending Doses of ABBV-1451 Infusions and Injections in Healthy Adult Participants
Research Team
A
ABBVIE CALL CENTER
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here